Literature DB >> 32925171

Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity.

Raj Vuppalanchi1, Marshall E McCabe1, Sweta R Tandra2, Siva P Parcha2, Adil Ghafoor2, Leslie Schuh2, Margaret M Inman2,3, Don J Selzer3, Dimitrios Stefanidis3, Naga Chalasani1.   

Abstract

OBJECTIVE: To assess the safety and efficacy of bariatric surgery in patients with cirrhosis. SUMMARY BACKGROUND DATA: Bariatric surgery may be a viable option for patients with cirrhosis and extreme obesity. However, the risk of liver decompensation after surgery is not thoroughly investigated.
METHODS: We conducted a case-controlled study with 106 obese patients with cirrhosis (cases) and 317 age, sex, body mass index-, and type of surgery-matched obese patients without cirrhosis (controls) who underwent bariatric surgery.
RESULTS: Patients with cirrhosis were predominantly Child-Pugh class A (97%) with the diagnosis established prior to surgery in only 46%. In the cirrhosis group, there was no death in the first 30 days compared with 1 patient in the control group. At 90 days there was 1 death in the cirrhosis group but no additional deaths in the control group. In total, 12 months after the surgery, there were 3 deaths in the cirrhosis group and 1 in the control group (2.8% vs 0.6%, P = 0.056). The surgery-related length of stay was significantly longer in patients with cirrhosis (3.7 ± 4.0 vs 2.6 ± 2.4 d, P = 0.001), but the 30-day readmission rate was lower (7.5% vs 11.9%, P = 0.001). The percent of total weight loss at 30 and 90-days was not significantly different between the groups and remained that way even at 1 year (29.1 ± 10.9 vs 31.2 ± 9.4%, P = 0.096).
CONCLUSIONS: Bariatric surgery in obese cirrhotic patients is not associated with excessive mortality compared with noncirrhotic obese patients.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 32925171     DOI: 10.1097/SLA.0000000000003891

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  2 in total

Review 1.  Comparative effectiveness of medical treatment vs. metabolic surgery for histologically proven non-alcoholic steatohepatitis and fibrosis: a matched network meta-analysis.

Authors:  Adrian T Billeter; Beatrice Reiners; Svenja E Seide; Pascal Probst; Eva Kalkum; Christian Rupp; Beat P Müller-Stich
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

Review 2.  Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.

Authors:  Sjaak Pouwels; Nasser Sakran; Yitka Graham; Angela Leal; Tadeja Pintar; Wah Yang; Radwan Kassir; Rishi Singhal; Kamal Mahawar; Dharmanand Ramnarain
Journal:  BMC Endocr Disord       Date:  2022-03-14       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.